Results 111 to 120 of about 17,407,911 (333)

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

XSEDE Cloud VM Repository [PDF]

open access: yes, 2016
The Technology Investigation Service's Technology Evaluation team produced a white paper to gather ideas for an XSED sponsored repository that would house VM's centrally.
The Technology Investigation Service's Technology Evaluation Team
core  

Retracted: Surface State Treatment of Carbon Dots Using Sulphur Dioxide Isotherm

open access: yesAdsorption Science & Technology, 2023
Adsorption Science and Technology
doaj   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

open access: yesMolecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Aspera Evaluation Report [PDF]

open access: yes, 2016
The Technology Investigation Service's Technology Evaluation team conducted an evaluation of the Aspera file transfer tool.
The Technology Investigation Service's Technology Evaluation Team
core  

Home - About - Disclaimer - Privacy